Dr. Michael Lim on Toxicities of Checkpoint Inhibitors in Glioblastoma
Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses checkpoint inhibitors in glioblastoma.
Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses checkpoint inhibitors in glioblastoma. Lim says medical professionals should be aware of the toxicities that come along with these checkpoint inhibitors, as well as be able to recognize the first signs of toxicities.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
